Capital Directions Investment Advisors’s Encompass Health EHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$5.02K Buy
+84
New +$4.57K ﹤0.01% 224
2022
Q3
Sell
-106
Closed -$5.3K 205
2022
Q2
$5K Hold
106
﹤0.01% 228
2022
Q1
$6K Buy
+106
New +$5.53K ﹤0.01% 243
2021
Q4
Sell
-106
Closed -$6K 107
2021
Q3
$6K Hold
106
﹤0.01% 242
2021
Q2
$7K Buy
+106
New +$7.07K ﹤0.01% 218
2021
Q1
Sell
-106
Closed -$7K 231
2020
Q4
$7K Hold
106
﹤0.01% 182
2020
Q3
$5K Hold
106
﹤0.01% 191
2020
Q2
$5K Hold
106
﹤0.01% 198
2020
Q1
$5K Hold
106
﹤0.01% 216
2019
Q4
$6K Hold
106
﹤0.01% 228
2019
Q3
$5K Buy
+106
New +$5.33K ﹤0.01% 227

Other funds holding EHC

Capital Directions Investment Advisors's EHC Position: Q4 2022 in Review

Capital Directions Investment Advisors opened a new position in Encompass Health (EHC) in Q4 2022: 84 shares worth $5.02K. The stake represents ﹤0.01% of the portfolio and ranks #224 among its holdings. This is a return to the name: Capital Directions Investment Advisors previously reported a position in EHC as recently as Q2 2022.

Capital Directions Investment Advisors first reported a position in EHC in Q3 2019 and has held it in 11 quarters since. The position peaked at $7K in Q2 2021. 377 funds tracked by Wall St. Rank hold EHC as of Q4 2022.

  • Capital Directions Investment Advisors held 84 shares of Encompass Health worth $5.02K as of Q4 2022.
  • Encompass Health was a new Capital Directions Investment Advisors position in Q4 2022.
  • Encompass Health made up ﹤0.01% of Capital Directions Investment Advisors's portfolio in Q4 2022, its #224 holding.
  • Capital Directions Investment Advisors first reported a position in Encompass Health in Q3 2019 and has held it in 11 quarters since.
  • Capital Directions Investment Advisors's Encompass Health position peaked at $7K in Q2 2021.
  • 377 funds tracked by Wall St. Rank held Encompass Health as of Q4 2022.

Based on Capital Directions Investment Advisors's 13F filing for Q4 2022, filed 1 Feb 2023.